Conventional Antiarrhythmics Class I-IV, Late INa Inhibitors, IKs Enhancers, RyR2 Stabilizers, Gap Junction Modulators, Atrial-Selective Antiarrhythmics, and Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Therapy in Arrhythmias.
This review paper proposes "cytoprotection" as a conceptual framework for evaluating antiarrhythmic drugs — defined as the ability to suppress arrhythmias while avoiding adverse electrophysiological or systemic effects. The authors systematically compare conventional antiarrhythmics (Classes I–IV) and newer agents (late INa inhibitors, IKs enhancers, RyR2 stabilizers, gap junction modulators, and atrial-selective antiarrhythmics), characterizing them as offering only partial cytoprotection over a narrow-to-moderate range. By contrast, the stable gastric pentadecapeptide BPC 157 is hypothesized to offer broader, "full-range" cytoprotective-antiarrhythmic effects. The authors cite preclinical rodent studies showing BPC 157 restoring sinus rhythm, normalizing ECG intervals, preventing AV block, suppressing ventricular tachycardia, and attenuating ST-segment changes across diverse arrhythmia models (hypo-/hyperkalemia, ischemia-reperfusion, drug-induced). In vitro HEK293 cell data reportedly show direct membrane-stabilizing actions. The authors acknowledge that human clinical data on BPC 157 remain limited and non-cardiac in nature, and explicitly call for translational clinical investigation. The paper's central claims about BPC 157 in arrhythmias rest almost entirely on preclinical and in vitro evidence, with no controlled human cardiac trials reported.
Why this grade: Although framed as a review, the BPC 157 antiarrhythmic claims are grounded exclusively in rodent in vivo models and HEK293 in vitro studies, with no human cardiac trial data reported.
This review examines and hypothesizes cytoprotection as a conceptual therapeutic criterion for antiarrhythmic drugs, referring to the possibility of suppressing arrhythmias while avoiding adverse electrophysiological or systemic effects. Toward a theoretically complete cytoprotective profile-preserving benefits and eliminating toxicity-the criterion was the degree of counteraction of arrhythmias (i.e., bradycardia, tachycardia, atrioventricular (AV) block, ventricular tachycardia (VT), ST-segment changes, prolonged P, PR, QRS, and QT/QTc intervals, and repolarization). Conventional and new antiarrhythmics share class I-IV ≈ partial cytoprotection/narrow range; late INa inhibitors, IKs enhancers, RyR2 stabilizers, gap junction modulators, and atrial-selective antiarrhythmics ≈ partial cytoprotection/more extended range. Still predominantly in preclinical models, stable gastric pentadecapeptide BPC 157, in the clinic, has not demonstrated adverse effects in available human trials (non-cardiac) to date. As a prominent cytoprotection mediator (LD1 not achieved in toxicology studies), it demonstrates well-matched cytoprotective-antiarrhythmic effects, BPC 157 ≈ full cytoprotection/wide-range homeostasis. In vivo, this was across models of hypo-/hyperkalemia, hypermagnesemia, ischemia-reperfusion, myocardial infarction, drug-induced arrhythmias (including local anesthetics), and vascular occlusion. BPC 157 restores sinus rhythm, normalizes P/QRS/QT intervals, prevents AV block, suppresses VT, attenuates ST-segment changes, and stabilizes heart rate, even when insults are advanced. In vitro, HEK293 studies confirm direct membrane-stabilizing actions: BPC 157 prevents hypokalemia-induced hyperpolarization, reduces hyperkalemia- and hypermagnesemia-induced depolarization, and mitigates local anesthetic-induced Na + /Ca 2+ dysregulation, reflecting bidirectional homeostatic modulation of membrane potential. Thus, to confirm the hypothesis, these BPC 157 conditional, not constitutive effects, in rodent models or in vitro systems (HEK293 cells), mandate expansion of now limited clinical data and mechanisms in human investigated as a translational cytoprotective strategy for complex arrhythmias.
Educational summary of published research — not medical advice. License: cc by. Full text is shown only where licensing permits.